Skip to main content
Trending
Corporate earningsAi infrastructureEnergy marketsElection litigationAviation safetyCrypto securityAi governanceEnterprise aiPlatform liabilityAvian influenzaClinical trialsFederal debtPresidential runoffRpg developmentSpace debrisAir defenseAutonomous vehiclesBudget crisisBug bountiesEnergy m&aForeign investmentFranchise restructuringGene therapyPandemic treatyTranslation pathwaysUn peacekeepingWeapons testingWeight-space programmingAi copyright lawArchaeological toxicology

full timeline

CAR T-Cell Therapy Successfully Targets Autoimmune Disease, Restoring Mobility in Stiff Person Syndrome Patients

One-year clinical trial data demonstrates that a single infusion of miv-cel CAR T-cell therapy provides sustained mobility improvements for patients with severe autoimmune disorders, without the need for ongoing immunosuppression.

Factlen Newsroom· Updated

Follow CAR T-Cell Therapy Successfully Targets Autoimmune Disease, Restoring Mobility in Stiff Person Syndrome Patients in the Factlen app and get an alert when there is news. Get the app

One-year data suggests CAR T-cell therapy can restore and maintain mobility in patients with severe autoimmune disorders.From: CAR T-Cell Therapy Shows Durable One-Year Mobility Improvement in Stiff Person Syndrome Trial

Share this story

Key numbers

80%
Patients achieving complete cessation of severe muscle spasms
$400,000+
Estimated current cost per dose of autologous CAR-T
0
Detectable anti-GAD65 antibodies at 6 months post-infusion

From: CAR T-Cell Therapy Successfully Targets Autoimmune Disease, Restoring Mobility in Stiff Person Syndrome Patients

Charts, maps and images

Patients in the trial maintained their functional mobility gains a full year after receiving the miv-cel infusion.From: CAR T-Cell Therapy Shows Durable One-Year Mobility Improvement in Stiff Person Syndrome Trial ·
How CAR T-cells trigger a deep immune reset by eliminating autoantibody-producing B cells.From: CAR T-Cell Therapy Successfully Targets Autoimmune Disease, Restoring Mobility in Stiff Person Syndrome Patients ·
Clinical trial data shows a rapid decline in disease-causing antibodies correlating with restored mobility.From: CAR T-Cell Therapy Successfully Targets Autoimmune Disease, Restoring Mobility in Stiff Person Syndrome Patients ·
Following the immune reset, patients who previously required mobility aids regained the ability to walk unassisted.From: CAR T-Cell Therapy Successfully Targets Autoimmune Disease, Restoring Mobility in Stiff Person Syndrome Patients ·

Timeline

September 2026

  1. CAR T-Cell Therapy Shows Durable One-Year Mobility Improvement in Stiff Person Syndrome Trial

July 2026

  1. CAR T-Cell Therapy Successfully Targets Autoimmune Disease, Restoring Mobility in Stiff Person Syndrome Patients